Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13995828 | 0.89 | EGLN3 (0.59) | EGLN3ALDH1A1FDPSMEN1KMT2A | |
| SCHEMBL28263721 | 0.83 | EGLN3 (0.74) | EGLN3ALDH1A1TNKS2FDPSMEN1 | |
| SCHEMBL7197057 | 0.82 | EGLN3 (1.00) | EGLN3ALDH1A1TNKS2FDPSMEN1 | |
| SCHEMBL10514858 | 0.81 | EGLN3 (0.65) | EGLN3ALDH1A1TNKS2FDPSMEN1 | |
| Hydrochloric Acid SCHEMBL10637029 | 0.80 | EGLN3 (0.96) | EGLN3ALDH1A1TNKS2FDPSPKM | |
| SCHEMBL10637015 | 0.80 | EGLN3 (0.69) | EGLN3ALDH1A1TNKS2FDPSMEN1 | |
| SCHEMBL1178524 | 0.80 | EGLN3 (0.69) | EGLN3ALDH1A1TNKS2FDPSMEN1 | |
| SCHEMBL30161886 | 0.79 | EGLN3 (0.62) | EGLN3ALDH1A1TNKS2MEN1KMT2A | |
| SCHEMBL18072254 | 0.79 | EGLN3 (0.62) | EGLN3ALDH1A1TNKS2MEN1KMT2A | |
| SCHEMBL10516198 | 0.79 | EGLN3 (0.62) | EGLN3ALDH1A1TNKS2FDPSMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117165127-A | Sealing material for hydrogen production electrolytic tank and gasket structure thereof | 镇江春环密封件集团有限公司 | 2023-12-05 | — | — | CN | claimed |
| CN-117165127-A | Sealing material for hydrogen production electrolytic tank and gasket structure thereof | 镇江春环密封件集团有限公司 | 2023-12-05 | — | — | CN | disclosed |
| US-20230312490-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| WO-2021133689-A2 | LIPOXYGENASE INHIBITORS | SRI INTERNATIONAL (US) | 2021-07-01 | — | — | WO | disclosed |
| US-10988451-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200331870-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2020-10-22 | — | — | US | disclosed |
| US-20190352271-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2019-11-21 | — | — | US | disclosed |
| US-8148373-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | disclosed |
| US-20090298807-A1 | Compounds | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2009-07-09 | — | — | US | disclosed |
| EP-0234622-B1 | NEW THIO COMPOUNDS HAVING FUNGICIDAL ACTIVITY | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1990-06-27 | — | — | EP | disclosed |
| EP-0329015-A2 | Substituted triazoles | BAYER AG (DE) | 1989-08-23 | — | — | EP | disclosed |
| EP-0297393-A2 | 1-Phenoxy-3-triazolyl-hex-1-ene-derivatives | BAYER AG (DE) | 1989-01-04 | — | — | EP | disclosed |
| EP-0116729-B1 | BENZOYLUREA COMPOUNDS AND PESTICIDAL COMPOSITIONS COMPRISINGSAME | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1988-10-12 | — | — | EP | disclosed |
| EP-0116728-B1 | COMPOSITION ACTIVE AGAINST MITES, WHITEFLY AND THRIPS, PHARMACEUTICAL COMPOSITION, AND NEW BENZOYLUREAU COMPOUNDS | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1987-08-12 | — | — | EP | disclosed |
| EP-0079635-B1 | ARYLPHENYL ETHERS HAVING HERBICIDAL ACTIVITY | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1986-05-21 | — | — | EP | disclosed |
| EP-0065334-B1 | NEW PYRAZOLINE DERIVATIVES, METHOD OF PREPARING THE NEW COMPOUNDS, AS WELL AS INSECTICIDAL COMPOSITIONS ON THE BASIS OF THESE COMPOUNDS | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1985-07-17 | — | — | EP | disclosed |
| EP-0031173-B1 | NEW NITROTHIOPHENES, METHOD OF PREPARING THE NEW COMPOUNDS, AS WELL AS FUNGICIDAL AND/OR BACTERICIDAL COMPOSITIONS ON THE BASIS OF THE NEW COMPOUNDS | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1983-09-14 | — | — | EP | disclosed |
| EP-0021506-B1 | NEW PYRAZOLINE DERIVATIVES, METHOD OF PREPARING THE NEW COMPOUNDS, AS WELL AS INSECTICIDAL COMPOSITION ON THE BASIS OF THESE NEW COMPOUNDS | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1983-09-07 | — | — | EP | disclosed |
| EP-0002678-A2 | Azolylalkyl-pyridinyl ethers, process for their preparation and their use as fungicides | BAYER AG (DE) | 1979-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352271-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | EGLN3 1613/4885ALDH1A1 1991/4885TNKS2 281/4885 |
| US-20200331870-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | EGLN3 1613/4885ALDH1A1 1991/4885TNKS2 281/4885 |
| US-20230312490-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | EGLN3 1613/4885ALDH1A1 1991/4885TNKS2 281/4885 |
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | EGLN3 348/4885ALDH1A1 438/4885TNKS2 2815/4885 |
| US-10988451-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | EGLN3 1613/4885ALDH1A1 1991/4885TNKS2 281/4885 |
| US-20090298807-A1 | Compounds | PKD1, SLC10A1, ABCB11 | EGLN3 1910/4885ALDH1A1 102/4885TNKS2 3991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.